December 1, 2020

Announces

SANTA CLARA, Calif.–(Business Wire)–Momentus Inc. (“Momentus” or the “Company”), a commercial space company offering in-space infrastructure services, and Gilmour Space Technologies, a leading hybrid rocket company based in Queensland, Australia, today announced a new agreement for launch and orbital transport services.

Under the agreement, Momentus will gain access to low inclination and equatorial orbits using Gilmour Space’s Eris launch services. With Momentus’ Vigoride transportation service, Gilmour Space will have the capability to expand the flight domain of the Eris rockets (the company has several larger models planned coming to market beginning in 2023) and enable constellation deployments and missions beyond low Earth orbit (LEO). Gilmour Space has the option to book up to three Vigoride charter missions for orbital transfer services from Momentus over the 2023-2025 period, while Momentus will purchase one dedicated Eris launch service from an Australian launch site.

“Momentus is proud to announce another partnership with the Australian space industry, shortly after sealing an agreement to launch Skykraft’s satellite in 2021,” said Mikhail Kokorich, CEO of Momentus. ”We are looking forward to supporting ambitious projects in partnership with Gilmour Space, such as flagship missions with the Australian Space Agency and development of sovereign space capabilities with the local industry.”

Gilmour Space is a venture-backed rocket company in Queensland, Australia that is developing new launch vehicles powered by lower-cost hybrid propulsion technologies. The Eris launch vehicle will debut its services in 2022 and offer lift-off capability to LEO in the 300kg class. A more capable variant, Eris Heavy, is intended to be commercially available in 2025 with a lift off capacity up to two tons. The Eris family of launch vehicles will launch from Australian and international launch sites, offering access to low inclination as well as Sun-synchronous orbits.

“This is the first international contract we’ve announced this year, and a great example of how innovative companies are coming together to accelerate development and provide new access to space,” said Gilmour Space CEO, Adam Gilmour.

About Momentus Inc.

As a first mover in building in-space infrastructure services, Momentus is at the forefront of the commercialization of space. With an experienced team of aerospace, propulsion, and robotics engineers, Momentus has developed a cost-effective and energy efficient in-space transport system based on water plasma propulsion technology. Momentus has in-place service agreements with private satellite companies, government agencies, and research organizations.

For more information visit http://www.momentus.space

About Gilmour Space Technologies Pty Ltd

Gilmour Space Technologies is a leading hybrid rocket company based in Queensland, Australia, that is developing a new breed of lower-cost, reliable and dedicated rockets that will launch small satellites into low earth orbits from 2022.

For more information visit https://www.gspacetech.com/

Momentus

Investors: [email protected]

Media: [email protected]

Gilmour Space

Media: Michelle Gilmour, [email protected]; +61 433 908 084

(function(){ window.fbAsyncInit = function() { djp.console('after FB source loaded, '+ typeof(FB)); djp.init_fb(); };

// Load the SDK Asynchronously (function(d){ var js, id = 'facebook-jssdk', ref = d.getElementsByTagName('script')[0]; if (d.getElementById(id)) {return;} js = d.createElement('script'); js.id = id; js.async …

...

Automotive Defense Specialists is a team of attorneys that works hard to secure the legal rights of auto repair technicians against the Bureau of Automotive Repair. The firm is proud to announce the continued success of its landmark post on the merits of an appeal.

SAN FRANCISCO – November 25, 2020 – (Newswire.com)

Automotive Defense Specialists, a law firm that represents auto shop station owners and repair technicians who participate in California’s SMOG and/or STAR Programs for air quality at https://automotivedefense.com/, is proud to announce the continued success of a landmark post on the merits of an appeal to California’s Bureau of Automotive Repair. 

“Many hard-working automotive repair technicians and repair shops are terrified when they receive a negative decision from California’s Bureau of Automotive Repair,” explained attorney William Ferreira of Automotive Defense Specialists. “We’re very proud of the continued success of our landmark post on the merits of an appeal to the Bureau. Many users have found the post and then reached out to us for a consultation on how to appeal a decision by the Bureau, including those that are related to SMOG issues.”

Interested persons can visit the post at https://automotivedefense.com/2020/02/02/if-you-receive-a-licensing-decision-from-the-bureau-of-automotive-repair-you-have-a-right-of-appeal/. The post, first published in February 2020, has now become a landmark for those on a journey to discover their rights to an appeal against the Bureau of Automotive Repair and then possibly reach out to an attorney for representation. Of course, there is no obligation one way or another; the best thing to do is to evaluate one’s options and then, if desired, to reach out to a professional for help. Only a trained attorney can evaluate the facts of the situation, the information provided by the Bureau of Automotive Repair in a decision or action, and the costs and benefits of an appeal.

A DEFENSE ATTORNEY FOR HARD-WORKING AUTO REPAIR TECHNICIANS

Here is the background for the release. Small business owners and hard-working auto repair technicians face a very difficult work environment in California. First, there are the enormous regulatory challenges in the auto repair and SMOG check industry. Climate change and new environmental regulations are ever-present from Sacramento and the important SMOG check industry is a fulcrum of the state’s strategy. But new regulations can be unclear, and their enforcement can seem arbitrary to a station owner or technician.

ABOUT AUTOMOTIVE REPAIR SPECIALISTS

Automotive Defense Specialists (https://automotivedefense.com/) is a top law firm representing auto repair facilities, SMOG check stations, and technicians in every facet of their legal needs, including Bureau of Automotive Repair letters, citations, and invalidations. The company offers phone consultations to auto shops, mechanics, technicians, and others who are facing disciplinary actions from the California Bureau of Automotive Repair.

Tel. (415) 392-2886

Related Links
Bureau of Automotive Repair
STAR Invalidation

Press Release Service
by
Newswire.com

Original Source:

Automotive Defense Specialists Announces Continued Success of Landmark Post on the Merits of a Bureau of Automotive Repair Appeal

(function(){ window.fbAsyncInit = function() { djp.console('after FB source loaded, '+ typeof(FB)); djp.init_fb(); };

// Load …

...

Firm capacity along Dawn-Kirkwall-Parkway paths starting in 2023 and 2024

TORONTO, Nov. 24, 2020 /PRNewswire/ – Enbridge Gas is holding an open season for M12 firm transportation service capacity of up to 100,000 GJ/d beginning on Nov. 1, 2023 and up to 250,000 GJ/d beginning on Nov. 1, 2024, for a minimum fifteen-year term along the following paths:

  • Dawn to Parkway
  • Dawn to Kirkwall
  • Kirkwall to Parkway
  • The Enbridge Gas Dawn-Parkway System is one of the most robust pipeline systems in North America and provides for the movement of natural gas from the Dawn Hub located near Sarnia, Ontario, to the Greater Toronto Area, where it interconnects with other downstream pipelines serving eastern Canadian and northeast U.S. markets. Dawn and the compressor stations located along the Dawn-Parkway corridor have loss of critical unit reserve horsepower coverage which provides firm service reliability.

    The Dawn Hub is one of the largest integrated natural gas storage facilities in North America. Strategically located in southwestern Ontario and with 280 Bcf of working capacity, it offers customers, such as power generators, distribution and pipeline companies and energy marketers, an important link in the movement of natural gas from key supply basins to markets in central Canada and the northeast U.S.

    The Dawn Hub also provides shippers with direct access to North America’s major supply basins, including Appalachia and Western Canadian Sedimentary Basin. With multiple supply routes from western Canada, the mid-continent, Appalachia and the Rockies, as well as the ability to serve markets in the mid-west, eastern Canada and the U.S. Northeast, the Enbridge Gas Dawn Hub is a reliable, secure, and liquid natural gas trading hub. For more information, visit www.uniongas.com/openseason.

    About Enbridge Gas Inc.
    Enbridge Gas Inc., formed on Jan. 1, 2019 from the amalgamation of Union Gas Limited and Enbridge Gas Distribution, is Canada’s largest natural gas storage, transmission and distribution company based in Ontario with a more than 170-year history of providing safe and reliable service to customers. The distribution business serves about 3.8 million customers, heating over 75 per cent of Ontario homes. The storage and transmission business offers a variety of storage and transportation services to customers at the Dawn Hub, the largest integrated underground storage facility in Canada and one of the largest in North America.  Enbridge Gas Inc. is owned by Enbridge Inc., a Canadian-based leader in energy transportation and distribution.

    Cision View original content:https://www.prnewswire.com/news-releases/enbridge-gas-announces-m12-transportation-service-open-season-301180016.html

    SOURCE Enbridge Gas Inc.

    Source Article

    ...

    City Transportation Commissioner Polly Trottenberg on Monday announced plans to resign in early December, nearly seven years after she joined Mayor de Blasio’s administration with the goal of reducing traffic deaths.

    Loading...

    Load Error

    Trottenberg — whose job oversaw the city’s streets, sidewalks and Staten Island Ferry — has been credited with pushing forward with the rollout of bike and bus lanes across the city, even when she sometimes lacked public support from the mayor.

    “I have been honored to work with them and see the passion, creativity and dedication they bring every day to serving New Yorkers, especially during the pandemic of the last eight months,” Trottenberg said in a statement. “For now, I just say thank you, one and all.”

    She was brought on to the top Department of Transportation role when de Blasio took office in 2014 after previously serving as undersecretary at the U.S. DOT under President Obama.

    Hizzoner put Trottenberg in charge of his Vision Zero program, which aimed to end traffic deaths across the five boroughs through street design and enforcement of reckless drivers.

    “This is something for the ages,” de Blasio said Monday of Trottenberg’s departure. “This city, a place known for so much intensity and so much activity, has actually been the place leading the nation in terms of how to be safer.”

    The Vision Zero program has been hailed as a model for other cities to improve street safety — but it’s had mixed results.

    After the city saw reductions in traffic fatalities during Trottenberg’s first five years at the helm, deaths ticked up last year and are on pace to increase again in 2020.

    The DOT has installed more than 100 miles of bike lanes since de Blasio took office, and Trottenberg pushed for a 2019 plan called the “Green Wave” with the goal of installing 80 new miles of protected bike lanes before the end of the mayor’s term in January 2022.

    That plan has been hindered by the COVID-19 pandemic — and in September seven cyclists died on city streets, the most in a single month since de Blasio took office.

    Trottenberg also served as de Blasio’s appointee on the Metropolitan Transportation Authority board from 2014 through 2019, and was praised by transit officials as a voice of reason in a room full of strong personalities.

    It’s unclear what’s next for Trottenberg, an avid cyclist who made a point to regularly ride her bicycle to work at the DOT’s lower Manhattan headquarters.

    She’s been appointed as a transportation adviser on President-elect Joe Biden’s transition team — and a return to federal government could be in the cards.

    De Blasio said he’ll likely tap a current DOT staffer to ride out the remainder of the term.

    “We have a very deep bench,” said de Blasio. “She’s got a great team she’s assembled, and we’ll be able to continue that work.”

    ———

    ©2020 New York Daily News

    Visit New York Daily News at www.nydailynews.com

    Distributed by Tribune Content Agency, LLC.

    Continue
    …...

    Ken Garff Automotive, LLC announced that it will host a conference call for current noteholders, prospective qualified institutional purchasers, and the trustee to discuss Q3 2020 financial results at 11 am MT on Friday, December 4, 2020.

    Instructions for the conference call will be made available to representatives of the trustee, noteholders, and prospective qualified institutional purchasers who currently have access to the Company’s private data room. Other noteholders and qualified institutional purchasers should contact Jim Campbell, CFO of Ken Garff Automotive, LLC to obtain access to the Company’s financial statements and information concerning the conference call.

    About Ken Garff Automotive

    Ken Garff Automotive, LLC is a private operator of automotive dealerships in the United States. We offer 26 brands of new and used vehicles in 52 stores that comprise 89 franchises. We have locations in six states with concentrations of stores in the West and Midwest regions of the United States. Our mission is to become the most esteemed automotive group as we treat people right and create lifetime customers.

    Source Article

    ...

    Bicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V.

    Bicycle Therapeutics plc (NASDAQ:BCYC), a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that it has entered into a settlement and license agreement with Pepscan Systems B.V. regarding Bicycle’s use of Pepscan’s CLIPS peptide technology.

    The companies have agreed to settle all intellectual property disputes worldwide. Under the terms of the settlement, Bicycle has been granted a license to use CLIPS peptide technology in the development of its product candidates BT1718 and THR-149. Bicycle will pay €3 million upfront, will pay €1 million on the first anniversary of the date of settlement, and will make potential additional payments to Pepscan based on achievement of specified clinical, regulatory and commercial milestones.

    About Bicycle Therapeutics

    Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles®, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle’s lead product candidate, BT1718, a Bicycle Toxin Conjugate (BTC) that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research UK. Bicycle is also evaluating BT5528, a second-generation BTC targeting EphA2, in a Company-sponsored Phase I/II study. BT8009 is a BTC targeting Nectin-4, a well-validated tumor antigen, and is also currently being evaluated a Company-sponsored Phase I/II trial. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.

    Forward-Looking Statements

    This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding Bicycle’s use of CLIPS peptide technology in the development of its product candidates BT1718 and THR-149, Bicycle’s future payment obligations to Pepscan, and Bicycle’s contemplated achievement of specified clinical, regulatory and commercial milestones. Bicycle may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as to Bicycle’s abilities to meet other anticipated deadlines and milestones, presented by the ongoing COVID-19

    …...

    CAMBRIDGE, England & BOSTON–(Business Wire)–Bicycle Therapeutics plc (NASDAQ:BCYC), a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that it has entered into a settlement and license agreement with Pepscan Systems B.V. regarding Bicycle’s use of Pepscan’s CLIPS peptide technology.

    The companies have agreed to settle all intellectual property disputes worldwide. Under the terms of the settlement, Bicycle has been granted a license to use CLIPS peptide technology in the development of its product candidates BT1718 and THR-149. Bicycle will pay €3 million upfront, will pay €1 million on the first anniversary of the date of settlement, and will make potential additional payments to Pepscan based on achievement of specified clinical, regulatory and commercial milestones.

    About Bicycle Therapeutics

    Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles®, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle’s lead product candidate, BT1718, a Bicycle Toxin Conjugate (BTC) that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research UK. Bicycle is also evaluating BT5528, a second-generation BTC targeting EphA2, in a Company-sponsored Phase I/II study. BT8009 is a BTC targeting Nectin-4, a well-validated tumor antigen, and is also currently being evaluated a Company-sponsored Phase I/II trial. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.

    Forward-Looking Statements

    This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding Bicycle’s use of CLIPS peptide technology in the development of its product candidates BT1718 and THR-149, Bicycle’s future payment obligations to Pepscan, and Bicycle’s contemplated achievement of specified clinical, regulatory and commercial milestones. Bicycle may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as to Bicycle’s abilities to meet other anticipated deadlines and milestones, presented by the ongoing COVID-19 pandemic; uncertainties inherent in the initiation and

    …...

    PHOENIX–(BUSINESS WIRE)–Knight-Swift Transportation Holdings Inc. (NYSE: KNX) (“Knight-Swift” or the “Company”), North America’s largest truckload transportation company, announced that effective November 13, 2020, Adam Miller has been appointed President of Swift Transportation Co., LLC (“Swift”), a wholly owned subsidiary of the Company. Mr. Miller will continue to serve as the Chief Financial Officer of Swift’s parent company, Knight-Swift. He will succeed Kevin Knight, who has served as the Acting President of Swift since the merger with Knight Transportation, Inc. (“Knight”) in September 2017. Mr. Knight will continue as Knight-Swift’s Executive Chairman of the Board with the primary focus of strategic growth.

    Kevin Quast has been appointed as the Chief Administrative Officer of Knight-Swift. He previously served as the Chief Operating Officer of Swift since the merger, a position similar to the one he held at Knight prior to the merger.

    David Jackson, Chief Executive Officer, commented, “Adam Miller and Kevin Quast are talented and proven leaders that have earned the respect of our organization over their 18- and 24-year careers, respectively, at Knight and recent involvement with Swift. They have been influential, along with several other key leaders, in the unprecedented merger success at Swift with dramatic profitability improvements for America’s largest full truckload carrier.”

    About Knight-Swift

    Knight-Swift Transportation Holdings Inc. is a provider of multiple truckload transportation and logistics services using a nationwide network of business units and terminals in the United States and Mexico to serve customers throughout North America. In addition to operating the country’s largest tractor fleet, Knight-Swift also contracts with third-party equipment providers to provide a broad range of truckload services to its customers while creating quality driving jobs for our driving associates and successful business opportunities for independent contractors.

    This press release contains certain statements that may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such statements are subject to the safe harbor created by those sections and the Private Securities Litigation Reform Act of 1995, as amended. All statements, other than statements of historical or current fact, are statements that could be deemed forward-looking statements, including, without limitation, statements relating to our future performance and growth. Forward-looking statements are based on the current beliefs, assumptions, and expectations of management and current market conditions. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause future events and actual results to differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. Readers should review and consider the factors that may affect future results and other disclosures in the Risk Factors section of Knight-Swift Transportation Holdings Inc.’s Annual Report on Form 10-K for the year ended December 31, 2019, Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, and various disclosures in our press releases, stockholder reports, and other filings with the Securities

    …...

    BALTIMORE, Nov. 18, 2020 (GLOBE NEWSWIRE) — MediGO, the next-generation hardware and software platform for organ transplantation logistics, today announced a partnership with FlightAware, leaders in providing advanced, accurate, actionable aviation data and insights. MediGO seamlessly integrates FlightAware’s data via AeroAPI (formerly FlightXML) into MediGO’s organ logistics and monitoring system, providing increased situational awareness and transparency throughout the organ transportation process. MediGO is the only solution on the market to offer this level of insight.

    Transporting an organ from donor to transplant recipient often includes several exchanges between ground and air services over long distances. While on the ground, organ location can be tracked by GPS; however, GPS transmitters do not work while in the cargo hold of an airplane and the communication of the hardware is shut off while in flight mode. Previously, organ procurement organizations (OPOs) and medical teams had little insight into the whereabouts of organs in transit. Now, for the first time, it will be possible to track the location of an organ in real-time regardless of mode of transportation including in the air with this alliance between MediGO and FlightAware.

    The unique calibration of the MediGO hardware and software enables seamless and timely transfers through the various modes of transportation in organ transport. The aviation component of the process utilizes FlightAware data to provide status updates to key OPO stakeholders. Upon take-off and landing, MediGO automatically and seamlessly switches between GPS tracking and the FlightAware data. This capability removes existing blind spots in the organ transportation process.

    “Our partnership and integration with FlightAware will allow MediGO to provide a higher level of service and more predictability in the organ transportation process,” said Chetan Paydenkar, General Manager of MediGO. “We’re the first and only application to monitor the organ in transit and provide updates during the entire journey with this FlightAware integration.”

    With the expansion of Donor Service Areas (DSA) by CMS for kidneys and pancreata, the transportation process becomes even more complicated, driving the need for better logistics and location monitoring for the transplant network.

    “Our goal at FlightAware is to provide reliable and actionable data to inform every aviation decision,” said Daniel Baker, CEO of FlightAware. “We’re proud to be helping MediGO’s mission of saving lives by making the transplantation process more efficient.”

    About MediGO
    MediGO is the next generation hardware and software platform for organ transplantation logistics. Located in Baltimore, Maryland, MediGO is focused on increasing access to organ transplantation by optimizing the transplant supply chain. MediGO offers real-time monitoring of organ transportation including location, temperature, and environmental factors that inform logistics decisions, current estimated time of arrival for organ shipments, and a centralized in-app communication system for all relevant stakeholders. For more information please visit gomedigo.io

    About FlightAware
    FlightAware is the leading provider of real-time and historical flight information and insights to the global aviation community. FlightAware serves all segments of the aviation marketplace through best-of-breed applications and data services that provide comprehensive information about the current and predicted movement of aircraft.

    …...